N-(((6S,7R)-7-(3,4-Dichlorophenyl)-1,4-oxazepan-6-yl)methyl)butyramide hydrochloride

ID: ALA4777709

PubChem CID: 66975003

Max Phase: Preclinical

Molecular Formula: C16H23Cl3N2O2

Molecular Weight: 345.27

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCCC(=O)NC[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(Cl)c1.Cl

Standard InChI:  InChI=1S/C16H22Cl2N2O2.ClH/c1-2-3-15(21)20-10-12-9-19-6-7-22-16(12)11-4-5-13(17)14(18)8-11;/h4-5,8,12,16,19H,2-3,6-7,9-10H2,1H3,(H,20,21);1H/t12-,16-;/m0./s1

Standard InChI Key:  DKCFGEFANJOESL-MIRNQTQTSA-N

Molfile:  

     RDKit          2D

 23 23  0  0  0  0  0  0  0  0999 V2000
   32.6835   -4.3295    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   30.4613   -1.4903    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.2616   -1.3196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.8944   -1.8437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.0903   -2.2267    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.8855   -2.6637    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.4388   -2.9693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.2383   -3.1650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.2690   -2.2143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8730   -1.4966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.0526   -1.4839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6284   -2.1859    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.0347   -2.9062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8539   -2.9154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.9167   -3.6055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2046   -4.3703    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.6862   -5.0021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.9742   -5.7669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8800   -4.8690    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.8113   -2.1736    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   27.6566   -0.7691    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   30.7804   -5.8999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0684   -6.6647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  3  1  0
  3  4  1  0
  2  5  1  0
  4  6  1  0
  5  7  1  0
  6  8  1  0
  7  8  1  0
  5  9  1  6
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14  9  1  0
  7 15  1  1
 15 16  1  0
 16 17  1  0
 17 18  1  0
 17 19  2  0
 12 20  1  0
 11 21  1  0
 18 22  1  0
 22 23  1  0
M  END

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 345.27

Molecular Weight (Monoisotopic): 344.1058

AlogP: 3.19

#Rotatable Bonds: 5

Polar Surface Area: 50.36

Molecular Species: BASE

HBA: 3

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 9.28

CX LogP: 2.80

CX LogD: 0.93

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.86

Np Likeness Score: -0.46

References

1. Yukawa T,Fujimori I,Kamei T,Nakada Y,Sakauchi N,Yamada M,Ohba Y,Ueno H,Takiguchi M,Kuno M,Kamo I,Nakagawa H,Fujioka Y,Igari T,Ishichi Y,Tsukamoto T.  (2016)  Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors-Part 2.,  24  (14.0): [PMID:27255177] [10.1016/j.bmc.2016.05.038]

Source

Source(1):

• Scientific Literature